Loading...
OTCM
GSGTF
Market cap28mUSD
Dec 31, Last price  
0.24USD
Name

Gensight Biologics SA

Chart & Performance

D1W1MN
No data to show
P/E
—
P/S
10.46
EPS
—
Div Yield, %
—
Shrs. gr., 5y
27.55%
Rev. gr., 5y
30.26%
Revenues
3m
+107.18%
908,4421,102,6933,559,9983,001,0003,702,0004,346,000700,0004,394,0005,276,0002,582,0001,267,0002,625,000
Net income
-14m
L-46.60%
-2,762,861-6,671,142-13,653,620-22,081,663-24,112,000-33,453,000-30,710,000-34,016,000-28,617,000-27,624,000-26,220,000-14,001,000
CFO
-13m
L-47.54%
-1,950,097-5,516,392-12,094,554-19,641,790-18,782,000-28,383,000-28,112,000-15,044,000-17,139,000-33,753,000-24,663,000-12,937,000
Earnings
May 29, 2025

Profile

GenSight Biologics S.A., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. Its lead product candidates include LUMEVOQ (GS010), a recombinant AAV2-based gene therapy, which is in Phase III clinical trials for the treatment of leber hereditary optic neuropathy caused by a mutated ND4 gene; and GS030, which is in Phase I/II clinical trial for the treatment of retinitis pigmentosa, as well as in preclinical stage to treat dry age-related macular degeneration. The company also develops products that are in preclinical stage targeting ophthalmic and neurodegenerative diseases. GenSight Biologics S.A. was incorporated in 2012 and is headquartered in Paris, France.
URL
https://www.gensight-biologics.com/
IPO date
Jul 13, 2016
Employees
45
Domiciled in
FR
Incorporated in
FR

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
2,625
107.18%
1,267
-50.93%
2,582
-51.06%
Cost of revenue
18,439
24,894
27,175
Unusual Expense (Income)
NOPBT
(15,814)
(23,627)
(24,593)
NOPBT Margin
Operating Taxes
21
(1,000)
5
Tax Rate
NOPAT
(15,835)
(23,626)
(24,598)
Net income
(14,001)
-46.60%
(26,220)
-5.08%
(27,624)
-3.47%
Dividends
Dividend yield
Proceeds from repurchase of equity
3,918
(156)
BB yield
-17.63%
0.10%
Debt
Debt current
13,899
17,380
2,429
Long-term debt
6,313
2,871
12,084
Deferred revenue
193
Other long-term liabilities
9,844
13,496
16,167
Net debt
17,748
18,117
3,270
Cash flow
Cash from operating activities
(12,937)
(24,663)
(33,753)
CAPEX
(10)
(252)
Cash from investing activities
17
209
172
Cash from financing activities
13,542
15,859
95
FCF
(12,723)
(21,903)
(24,441)
Balance
Cash
2,464
2,134
10,610
Long term investments
633
Excess cash
2,333
2,071
11,114
Stockholders' equity
(233,526)
(221,639)
(26,467)
Invested Capital
235,563
222,861
40,170
ROIC
ROCE
EV
Common stock shares outstanding
95,800
48,316
46,330
Price
0.27
-41.30%
0.46
-86.32%
3.36
-39.53%
Market cap
25,866
16.38%
22,226
-85.73%
155,762
-37.95%
EV
43,614
40,343
356,680
EBITDA
(14,755)
(20,593)
(23,532)
EV/EBITDA
Interest
3,153
2,650
Interest/NOPBT